ReviewBiochimica et biophysica acta2015
Lung cancer: Biology and treatment options.
Review in Biochimica et biophysica acta, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 515 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Dyad-based Multiple Behavior Intervention for Reducing Lung Cancer Symptoms - a Pilot Randomized Control Trial (Breathe Easier II)
Understanding Lung Cancer Related Risk Factors and Their Impact
Who cites it
515 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,016 citations in OpenAlex.
- Pretreatment CT Texture Analysis for Predicting Survival Outcomes in Advanced Nonsmall Cell Lung Cancer Patients Receiving Immunotherapy: A Systematic Review and Meta-Analysis.Thoracic cancer · 2025Pooled it
- Systematic review and meta‑analysis of factors predicting postoperative lung function after lung cancer resection.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2024Pooled it
- The safety and efficacy of binimetinib for lung cancer: a systematic review.BMC pulmonary medicine · 2024Pooled it
- Therapeutic vaccines for advanced non-small cell lung cancer.The Cochrane database of systematic reviews · 2024Pooled it
- Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Pooled it
- Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023.Frontiers in oncology · 2024Pooled it
- Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies.Cancer research communications · 2023Pooled it
- The importance microRNAs as a biomarker in lung cancer.Acta bio-medica : Atenei Parmensis · 2023Pooled it
- Non-small cell lung cancer withFrontiers in oncology · 2023Pooled it
- Distinguishing EGFR mutant subtypes in stage IA non-small cell lung cancer using the presence status of ground glass opacity and final histologic classification: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- The effect of perioperative immunonutritional support on nutritional and inflammatory status in patients undergoing lung cancer surgery: a prospective, randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Trial
- Dose-related cardiac side effects and its impact on survival following thoracic radiotherapy: A scoping review.Clinical and translational radiation oncology · 2027Review
- Lung Cancer Patients Display Increased Expression of Bovine Meat and Milk Factor (BMMF) Proteins in Peritumor Alveolar Macrophages.International journal of cancer · 2026Article
- Patient and Caregiver Information-seeking in Lung Cancer Treatment: A Real-world Sentiment Analysis of Reddit Communities.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Targeting endoplasmic reticulum stress to attenuate cisplatin resistance in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2026Article
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer.Scientific reports · 2026Article
- Effects of Information Source Characteristics on Trust and Health Information Behaviours Among Individuals with Different Levels of Cyberchondria.Behavioral sciences (Basel, Switzerland) · 2026Article
- Epigenetics in lung cancer precision medicine: from bench to bedside-a narrative review.Translational lung cancer research · 2026Review
- Oxidative stress-driven mRedox biology · 2026Article
- Tumor-associated collagen signature in relation to metastasis in lung adenocarcinoma.Journal of thoracic disease · 2026Article
455 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Lung cancer remains the leading cause of cancer mortality in men and women in the U.S. and worldwide. About 90% of lung cancer cases are caused by smoking and the use of tobacco products. However, other factors such as radon gas, asbestos, air pollution exposures, and chronic infections can contribute to lung carcinogenesis. In addition, multiple inherited and acquired mechanisms of susceptibility to lung cancer have been proposed. Lung cancer is divided into two broad histologic classes, which grow and spread differently: small-cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs). Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, and targeted therapy. Therapeutic-modalities recommendations depend on several factors, including the type and stage of cancer. Despite the improvements in diagnosis and therapy made during the past 25 years, the prognosis for patients with lung cancer is still unsatisfactory. The responses to current standard therapies are poor except for the most localized cancers. However, a better understanding of the biology pertinent to these challenging malignancies, might lead to the development of more efficacious and perhaps more specific drugs. The purpose of this review is to summarize the recent developments in lung cancer biology and its therapeutic strategies, and discuss the latest treatment advances including therapies currently under clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.